Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 7, 2014, Pages 1904-1909

  Gu, Zhenyang ^a   Cai, Bo ^a   Yuan, Lei ^a   Li, Honghua ^a   Huang, Wenrong ^a   Jing, Yu ^a   Zhu, Haiyan ^a   Zhao, Yu ^a   Bo, Jian ^a   Wang, Quanshun ^a   Han, Xiaoping ^a   Yu, Li ^a   Gao, Chunji ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Hematopoietic stem cell transplantation; Post transplant lymphoproliferative disorder; Reduction of immunosuppression; T cell lymphoblastic lymphoma

Indexed keywords

EID: 84905647738     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gottschalk S, Rooney CM and Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44.
2. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr and Deeg HJ. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.
3. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
4. Williams H and Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107: 862-869.
5. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008.
6. Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, Wagner JE and Filipovich AH. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251-258.
7. Loren AW, Porter DL, Stadtmauer EA and Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145-155.
8. Green M and Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003; 50: 1471-1491.
9. Thorley-Lawson DA and Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337.
10. List AF, Greco FA and Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987; 5: 1673-1689.
11. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, Ljungman P, Engelhard D; Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757-770.
12. Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M and Messina C. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation 2010; 89: 1533-1540.
13. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
14. Chiu LS, Choi PC, Luk NM, Chang M and Tang WY. Spontaneous regression of primary cutaneous Epstein-Barr virus-positive, CD30-positive anaplastic large T-cell lymphoma in a heart-transplant recipient. Clin Exp Dermatol 2009; 34: e21-24.
15. Krenauer A, Moll A, Ponisch W, Schmitz N, Niedobitek G, Niederwieser D and Aigner T. EBVassociated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report. Diagn Pathol 2010; 5: 21.
16. Minauchi K, Koizumi K, Kondo M, Takigami M, Harada H, Fujita H and Mukai M. [Remission induced by dose-reduction of immunosuppressants alone in a patient with post-transplant lymphoproliferative disorder of central nervous system origin]. Rinsho Ketsueki 2011; 52: 272-277.
17. Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P and Amrolia PJ. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011; 155: 377-385.
18. Lieberman F, Yazbeck V, Raptis A, Felgar R and Boyiadzis M. Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. J Neurooncol 2012; 107: 225-232.
19. Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, Krok KL, Goldberg LR, Porter DL, Stadtmauer EA and Tsai DE. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar). Am J Transplant 2011; 11: 336-347.